

MEDICAMEN Biotech Limited



Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Ref: STEX/OUTCOME/2023-24

Date: 29.05.2023

BSE Limited 25th Floor Phiroze Jeejeebhoy Towers Dalal Street, Mumbai 400 001 BSE Code-531146	National Stock Exchange of India Limited Exchange Plaza, C-1, Block - G Bandra Kurla Complex Bandra (East) Mumbai - 400 051 NSE Code: MEDICAMEQ
---	--

Sub. : Outcome of Board Meeting

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended on March 31, 2023.

Pursuant to Regulation 30 & 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- Statement showing the Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and year ended on March 31, 2023 as **Annexure-A** and
- Statutory Audit Report on the Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and year ended on March 31, 2023 as **Annexure-B**

Further Board of Directors at their meeting approved the following resolutions:

- Recommended a final dividend @ 10% on Equity Shares of Rs. 10/- each i.e. Re 1/- per Equity Share for the Financial Year 2022-23.
- Appointment of M/s SPB & Co., Cost Accountants as Cost Auditor of the Company for the financial year 2023-24.
- Appointment of M/s Cheena & Associates as Internal Auditor of the Company for the financial year 2023-24.
- Appointment of M/s AMJ & Associates, Company Secretaries as Secretarial Auditor of the Company for the financial year 2023-24.

Please note that the reports of Auditors are with unmodified opinion with respect to the Audited Financial Results of the Company for the quarter/financial year ended March 31, 2023.

Please also find enclosed herewith declaration as per Regulation 33(3)(d) of SEBI (LODR), 2015 in respect of Auditor's Report with un-modified opinion for the Audited Financial Results for the quarter and year ended 31st March 2023.

The meeting of the Board of Directors commenced on 02.30 p.m. and concluded at 04.00 p.m.



Works: SP-1192, A & B Phase-IV, Industrial Area, Distt. Alwar, Bhiwadi - 301019 (Rajasthan),

Works: Unit-I : Plot No.: 86 & 87, Sector-6A, Unit-II : Plot No. : 84 & 85, Sector-6A, IIE, SIDCUL, BHEL, Ranipur, Haridwar - 249403, (Uttarakhand)

The Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and year ended on March 31, 2023, as approved by the Board, will also be available on the Company's website www.medicamen.com.

This is for your information and records.

Thanking You.

Yours faithfully,

For Medicamen Biotech Limited



Parul Choudhary
Company Secretary
ACS44157





MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, www.medicamen.com

Audited Standalone and Consolidated Financial Results for the Quarter and Year ended as on 31st March' 2023

PART I

(All figures are in Rs. Lacs, Except EPS)

		Standalone					Consolidated				
		Three Month period Ended			Year Ended		Three Month period Ended			Year Ended	
	Particulars	31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2022	31.03.2023	31.12.2022	31.03.2022	31.03.2023	31.03.2022
		Audited	Un-audited	Audited	Audited	Audited	Audited	Un-audited	Audited	Audited	Audited
1	Income from operations										
	(a) Net Sales / Income from operations	3,714.83	3,411.55	2,275.38	13,788.40	11,544.52	3,866.54	3,558.18	2,275.38	14,086.74	11,544.52
	(b) Other Income	34.65	62.87	33.76	246.22	172.01	34.65	62.87	33.76	246.22	172.01
	(c) Total Revenue	3,749.48	3,474.42	2,309.14	14,034.62	11,716.53	3,901.19	3,621.05	2,309.14	14,332.96	11,716.53
2	Expenses										
	a) Cost of Material Consumed	2,247.98	2,285.02	1,091.86	8,180.29	5,569.07	2,215.94	2,317.06	1,091.86	8,180.29	5,569.07
	b) Purchase of Goods Traded	-	-	-	-	-	-	-	-	-	-
	c) Changes in inventory of Finished Goods and Work in Progress	(109.86)	(619.22)	(40.61)	(1,029.82)	(333.63)	(50.99)	(619.22)	(40.61)	(970.95)	(333.63)
	d) Employees Benefits Expenses	437.94	493.61	384.30	1,856.88	1,450.19	551.93	567.12	384.30	2,044.38	1,450.19
	e) Finance Cost	85.76	68.19	56.39	292.27	140.06	85.76	68.19	56.39	292.27	140.06
	f) Depreciation and Amortisation Expenses	160.97	160.13	152.41	635.35	577.14	162.28	160.13	152.41	636.66	577.14
	g) Other expenses	462.00	665.51	341.95	2,366.38	2,503.35	500.73	705.51	342.89	2,445.82	2,504.29
	Total Expenses	3,284.78	3,053.24	1,986.30	12,301.34	9,906.18	3,465.64	3,198.79	1,987.23	12,628.46	9,907.11
3	Profit/(Loss) before Exceptional Items & Tax (1 - 2)	464.70	421.18	322.84	1,733.28	1,810.35	435.55	422.26	321.91	1,704.50	1,809.42
4	Exceptional Items (Commercial Tax Expenses Related to Earlier Years)	-	-	-	-	-	-	-	-	-	-
5	Profit/(Loss) before Extra Ordinary Items & Tax (3 - 4)	464.70	421.18	322.84	1,733.28	1,810.35	435.55	422.26	321.91	1,704.50	1,809.42
6	Tax Expenses										
	Current Year	107.50	78.42	53.45	369.96	397.69	107.51	78.42	53.45	369.96	397.69
	MAT Credit Entitlement	-	-	-	-	-	-	-	-	-	-
	Deferred Tax Liability	(47.40)	(33.18)	(6.08)	(136.88)	(77.98)	(48.83)	(33.18)	(6.08)	(138.31)	(77.98)
	Total Tax Expense	60.10	45.24	47.37	233.08	319.71	58.68	45.24	47.37	231.65	319.71
7	Net Profit /Loss for the period from Continuing operation (5- 6)	404.60	375.94	275.47	1,500.20	1,490.64	376.87	377.02	274.54	1,472.85	1,489.71

R. Bishnoi

	Particulars	31.03.2023 Audited	31.12.2022 Un-audited	31.03.2022 Audited	31.03.2023 Audited	31.03.2022 Audited	31.03.2023 Audited	31.12.2022 Un-audited	31.03.2022 Audited	31.03.2023 Audited	31.03.2022 Audited
8	Other Comprehensive Income	-	-	-	-	-	-	-	-	-	-
9	Item that will not reclassified to Profit & Loss	-	-	-	-	-	-	-	-	-	-
9	Total Comprehensive Income net of Tax	404.60	375.94	275.47	1,500.20	1,490.64	376.87	377.02	274.54	1,472.85	1,489.71
10	Net Profit/(Loss) attributable to										
	a) Controlling Interest	-	-	-	-	-	388.97	376.48	-	1,484.41	-
	b) Non-Controlling Interest	-	-	-	-	-	-12.10	0.54	-	-11.56	-
11	Paid up equity share capital (Rs. 10/- per share)	1,265.11	1,265.11	1,221.66	1,265.11	1,221.66	1,265.11	1,265.11	1,221.66	1,265.11	1,221.66
12	Earning Per Share (Rs.)										
	Basic	3.25	2.97	2.25	12.04	12.20	3.03	2.98	2.25	11.82	12.19
	Diluted	3.25	2.97	2.25	12.04	12.20	3.03	2.98	2.25	11.82	12.19

NOTES :

- The above Audited standalone and consolidated financial results for the quarter and year ended March 31, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors of the company at its meeting held on 29th May 2023. The above results have been audited by the statutory auditors of the Company. The reports of the statutory auditors are unqualified.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules there under and in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July 5, 2016 and other recognized accounting practices and policies to the extent applicable.
- The Board of Directors have recommended a final dividend @ 10% on Equity Shares of Rs. 10/- each i.e. Re 1/- per Equity Share subject to approval of the members of the company in ensuing Annual General Meeting.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - "Earning per Share".
- The other expenses and Employee benefits expenses includes Rs. 3.50 Crores approximately incurred during Financial Year 2022-23 on creating domestic marketing network for Oncology products.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.
- The figures of the last quarter ended March 31, 2023 and March 31, 2022 are the balancing figures between audited figures in respect to full financial year and the published unaudited year to date figure upto the period end of the third quarter of the relevant financial year, which were subject to limited review.

For & on behalf of Board of Directors
Medicamen Biotech Limited



R. Bishnoi

(Rahul Bishnoi)
Chairman

Place : New Delhi
Dated : 29.05.2023

**MEDICAMEN BIOTECH LIMITED**

1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

STANDALONE AND CONSOLIDATED ASSETS AND LIABILITIES AS AT 31.03.2023

PARTICULARS	STANDALONE		CONSOLIDATED	
	31.03.2023 (Amount Rs. Lacs)	31.03.2022 (Amount Rs. Lacs)	31.03.2023 (Amount Rs. Lacs)	31.03.2022 (Amount Rs. Lacs)
I. ASSETS				
Non-current assets				
Property, plant and Equipment	9,146.60	9,211.75	9,175.88	9,211.75
Other Intangible Assets	89.77	35.98	89.77	35.98
Capital work-in-progress	-	-	-	-
Financial Assets				
Investments	407.65	206.14	-	-
Loans & Advance	108.94	86.52	110.66	86.52
Deferred Tax Assets (net)	186.52	49.64	187.95	49.64
Other non-current assets	1,941.85	881.69	1,951.20	881.69
Total Non Current Assets	11,881.33	10,471.72	11,515.46	10,265.58
Current assets				
Inventories	4,505.73	2,700.97	4,505.73	2,700.97
Financial Assets				
Trade Receivables	6,022.54	6,117.84	6,525.81	6,322.35
Cash and cash equivalents	2,044.29	381.49	2,077.88	382.48
Loans & Advance	690.35	526.38	692.59	526.38
Other Current Assets	2,534.00	2,371.59	2,534.26	2,371.59
Total Current Assets	15,796.91	12,098.27	16,336.27	12,303.77
TOTAL ASSETS	27,678.24	22,569.99	27,851.73	22,569.35
II. EQUITY AND LIABILITIES				
Equity				
Share Capital	1,265.11	1,221.66	1,265.11	1,221.66
Other Equity	18,114.49	13,582.12	18,076.30	13,425.31
Total Equity	19,379.60	14,803.78	19,341.41	14,646.97
Non-current liabilities				
Financial Liabilities				
Borrowings	86.96	507.36	86.96	507.36
Provisions	166.01	145.94	166.01	145.94
Total Non Current Liabilities	252.97	653.30	252.97	653.30
Current Liabilities				
Financial Liabilities				
Borrowings	2,331.31	1,927.50	2,331.31	1,927.50
Trade payables	4,554.54	4,173.83	4,758.59	4,330.00
Other Current liabilities	720.83	502.89	728.46	502.89
Provisions	69.03	82.31	69.03	82.31
Current tax liabilities (Net)	369.96	426.38	369.96	426.38
Total Current Liabilities	8,045.67	7,112.91	8,257.35	7,269.08
TOTAL EQUITY & LIABILITIES	27,678.24	22,569.99	27,851.73	22,569.35

For and on behalf of the Board
Medicamen Biotech Limited(Rahul Bishnoi)
Chairman

Place : New Delhi

Date: 29.05.2023

**MEDICAMEN BIOTECH LIMITED**

1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

STANDALONE AND CONSOLIDATED CASH FLOW STATEMENT FOR THE PERIOD 01.04.2022 TO 31.03.2023

(All Fig. in Rs. Lacs)

Particulars	STANDALONE		CONSOLIDATED	
	2022-23 (Amount Rs. Lacs)	2021-22 (Amount Rs. Lacs)	2022-23 (Amount Rs. Lacs)	2021-22 (Amount Rs. Lacs)
CASH FLOW FROM OPERATING ACTIVITIES				
Net Profit/(Loss) after tax from continuing operations	1,500.20	1,490.64	1,472.85	1,489.71
Non-cash adjustment to reconcile profit before tax to net cash flows				
Provision for Taxation	369.96	397.69	369.96	397.69
Adjustment for Deferred Tax	-136.88	-77.98	-138.31	-77.98
Financial Charges	292.27	140.06	292.27	140.06
Loss/(profit) on sale of fixed assets	-0.68	-0.12	-0.68	-0.12
Depreciation/amortization on continuing operation	635.35	577.14	636.66	577.14
Interest income	-72.07	-13.54	-72.07	-13.54
Operating profit before working capital changes	2,588.15	2,513.89	2,560.68	2,512.96
Movement of working capital				
Increase/(decrease) in trade payables	380.72	1,216.19	428.59	1,108.86
Increase / (decrease) in long-term provisions	20.07	30.39	20.07	30.39
Increase / (decrease) in short-term provisions	-439.66	-366.54	-439.66	-411.98
Increase/(decrease) in other current liabilities	217.94	3.78	225.57	12.49
Decrease/(increase) in trade receivables	95.30	-1,142.50	-203.46	-1,067.61
Decrease/(increase) in inventories	-1,804.76	-2,180.57	-1,804.76	-2,180.59
Decrease / (increase) in long-term loans and advances	-22.42	-8.98	-24.14	-8.98
Decrease / (increase) in short-term loans and advances	-163.97	187.57	-166.21	507.57
Decrease/(increase) in other current assets	149.93	673.53	149.67	353.53
Decrease/(increase) in other Non-current assets	-1,060.14	-125.73	-1,063.29	-125.73
Direct taxes paid	-312.34	-320.00	-312.34	-320.00
Net cash flow from/ (used in) operating activities (A)	-351.18	481.03	-629.28	410.91
CASH FLOWS FROM INVESTING ACTIVITIES				
Purchase of fixed assets including intangible & CWIP	-623.31	-860.82	-660.11	-860.82
Purchase of non-current investments	-201.51	-	-	-
Interest received	72.07	13.54	72.07	13.54
Net cash flow from/(used in) investing activities (B)	-752.75	-847.28	-588.04	-847.28
CASH FLOWS FROM FINANCING ACTIVITIES :				
Proceeds from issuance of share capital	43.45	-	43.45	-
Proceeds from Securities Premium	3,037.16	-	3,037.16	-
Shares Warrants / Share Application Money	112.55	-	260.55	-
Capital Reserve	-	-	-2.00	-9.52
Long-term borrowings net of repayment / Repayment	-420.40	-133.10	-420.40	-133.10
Proceeds from short-term borrowings	403.81	834.63	403.81	834.64
Interest paid	-292.27	-140.06	-292.27	-140.06
Dividends paid on equity shares	-126.51	-122.17	-126.51	-122.17
Income Tax Provision Reverse for earlier year	50.34	-	50.34	-
Preferential issue Expenditure	-41.40	-	-41.40	-
Net cash flow from/(used in) in financing activities (C)	2,766.73	439.30	2,912.73	429.79
Net increase/(decrease) in cash and cash equivalents (A + B + C)	1,662.80	73.05	1,695.40	-6.58
Cash and cash equivalents at the beginning of the year	381.49	308.44	382.48	389.06
Cash and cash equivalents at the end of the year	2,044.29	381.49	2,077.88	382.48

For and on behalf of the Board
Medicamen Biotech Limited(Rahul Bishnoi)
ChairmanPlace : New Delhi
Date: 29.05.2023

**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE
FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS****TO THE BOARD OF DIRECTORS OF MEDICAMEN BIOTECH LIMITED****Report on the audit of the Standalone Financial Results****Opinion**

We have audited the accompanying statement of quarterly and year to date financial results of Medicamen Biotech Limited (the "Company") for the quarter ended March 31, 2023 and for the year ended March 31, 2023 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulation").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

- i) is presented in accordance with the requirements of the Listing Regulations in this regard; and
- ii) gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2023.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibilities for the Financial Results

The Statement has been prepared on the basis of the annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable accounting

standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(1) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.

- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.


We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the quarter ended March 31, 2023 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2023 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For Rai Qimat & Associates
Chartered Accountants



UDIN: 23080857BGYGUO5413
(FRN:013152C)
(Membership Number: 080857)

Place: Gurugram
Date: 29.05.2023

6

**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED
FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS**

TO THE BOARD OF DIRECTORS OF MEDICAMEN BIOTECH LIMITED

Report on the audit of the Consolidated Financial Results

Opinion

We have audited the accompanying statement of quarterly consolidated financial results of Medicamen Biotech Limited ("Holding Company"), which includes its subsidiaries (the Holding company and its subsidiaries together referred to as 'the Group') for the quarter and year ended March 31, 2023 ("Statement"), attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of the other auditors on separate audited financial statements of the subsidiaries/controlled entity, the Statement includes the results of the following entities:

i) Subsidiaries

- 1- Opal Pharmaceuticals Pty Ltd
- 2- Medicamen Life Sciences Private Limited

- ii) is presented in accordance with the requirements of the Listing Regulations in this regard; and
- iii) gives a true and fair view in conformity with the applicable accounting standards, and other accounting principles generally accepted in India, of the consolidated net profit and other comprehensive loss and other financial information of the Group for the quarter and year ended March 31, 2023.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs), as specified under Section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Consolidated Financial Results" section of our report. We are independent of the Group and its subsidiaries in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the consolidated financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with

Management's Responsibilities for the Consolidated Financial Results

The Statement has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of the Statement that give a true and fair view of the net profit and other comprehensive loss and other financial information of the Group in accordance with the applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are also responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances- Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial statements and other results/financial information of the entities within the Group to express an opinion on the Statement. We are responsible for the direction, supervision and performance of the audit of the financial information of such entities included in the Statement of which we are the independent auditors. For the other entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMDI/4412019 dated March 29, 2019 issued by the Securities Exchange Board of India under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMDI/4412019 dated March 29, 2019 issued by the Securities Exchange Board of India under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

Other Matter

The accompanying Statement includes the audited financial results, in respect of two subsidiaries, whose financial results/statements include total assets of Rs 173.49 lakhs as at March 31, 2023, total revenues of Rs. 151.71 lakhs and Rs.298.34 lakhs, total net profit after tax of Rs. (27.73) lakhs and Rs. (27.35) lakhs, for the quarter and the year ended on that date respectively, and net cash outflows of Rs. 146 lakh for the year ended March 31, 2023, as considered in the Statement which have been audited by their respective independent auditors.

The independent auditor's report on the standalone financial results of these entities have been furnished to us by the Management and our opinion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the reports of such auditors and the procedures performed by us as stated above.

For Rai Qimat & Associates
Chartered Accountants



UDIN: 23080857BGYGUR2073

(FRN:013152C)

(Membership Number: 080857)

Place: Gurugram
Date: 29.05.2023

MEDICAMEN Biotech Limited



Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Date: 29.05.2023

To

BSE Limited 25th Floor Phiroze Jeejeebhoy Towers Dalal Street, Mumbai 400 001 BSE Code-531146	National Stock Exchange of India Limited Exchange Plaza, C-1, Block - G Bandra Kurla Complex Bandra (East) Mumbai - 400 051 NSE Code: MEDICAMEQ
---	--

Subject: Declaration pursuant to Regulation 33 (3) (d) of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

Pursuant to Regulation 33 (3) (d) of the Listing Regulations, as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016, vide notification no. SEBI/LAD-NRO/GN/2016-17/001 dated May 25, 2016, Circular No CIR/CFD/CMD/56/2016 dated May 27, 2016 and Circular No CIR/CFD/CMD/56/2016 dated July 5, 2016, we hereby declare that M/s Rai Qimat & Associates, Chartered Accountants (Firm Registration No 013152C), statutory auditors of the Company have issued audit report with unmodified opinion on the audited financial results of the Company (Standalone & Consolidated) for the financial year ended on March 31 2023.

This is for your information and record.

Thanking you

Yours truly
For Medicamen Biotech Limited



Rahul Bishnoi
Director
DIN: 00317960